The Abdala coronavirus vaccine, which was developed at the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba, has shown 100 percent effectiveness against death from COVID-19, as well as severe disease, Cubadebate reports.
Such data were obtained by scientists based on the results of the third phase of testing. More than 48 thousand volunteers from 18 medical centers took part in it. The vaccine developed by CIGB is a three-component vaccine.
Earlier it was announced that the effectiveness of the drug against the symptomatic manifestation of COVID-19 is 92.28%.
The Cuban regulator, the Center for State Control of Medicines, Equipment and Medical Devices (CECMED), authorized the emergency use of the vaccine on the island on July 9.
According to the Cuban Foreign Ministry, by July 17, all three components of the drug Abdala had received 2 million people, one dose – 3.2 million.
A total of five coronavirus vaccines are being developed in Cuba. Another drug, whose trials are in the final stages, – Soberana 02 – showed 62% effectiveness in June based on the results of testing two doses (the vaccine consists of three doses in total). The research was conducted not on the basis of the original strain of coronavirus, but on the basis of a combination of variants of the virus circulating in Havana.
According to Johns Hopkins University, during the pandemic in Cuba, 269.6 thousand cases of coronavirus infection were detected, 1.7 thousand people died.
